Motor Neuron Disease Detection via Specific miRNA Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating motor neuron diseases, such as ALS, lack specificity and effectiveness, with no reliable tests available for early detection and existing therapeutics providing only marginal benefits.
Innovation Solution
The development of methods to detect and modulate motor neuron-specific miRNAs, including miR-218, miR-138, miR-133a, miR-133b, miR-1193, miR-34b, and miR-379, for early detection, treatment, and monitoring of motor neuron disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods are used for motor neuron diseases, then general disease detection is possible, but early and accurate detection is not achieved
Solution Approach 1:
The invention changes the detection parameter from general neurological assessments to specific miRNA expression levels (such as miR-218, miR-138, miR-133a, miR-133b, miR-1193, miR-34b, and miR-379). By measuring these specific molecular biomarkers in biological samples like blood or CSF, the method achieves both early detection and high accuracy simultaneously, resolving the contradiction between detection precision and time loss.
2Reliability
If existing therapeutics are administered for motor neuron diseases, then symptom management is provided, but disease progression is not effectively slowed
Solution Approach 1:
The invention establishes a feedback mechanism by monitoring miRNA expression levels in patients receiving treatment. By measuring changes in specific miRNA levels (such as miR-218 and miR-138) over time, clinicians can assess treatment efficacy and adjust therapies accordingly. This feedback loop enables more reliable treatment outcomes and better control of disease progression compared to traditional empiric therapy.
Data Source
AI summary
The present invention relates to compositions and methods for detecting motor neuron-specific miRNAs in a population of cells or subject. More particularly, the invention relates to detecting motor neuron-specific miRNAs to detect and treat motor neuron diseases associated with dysregulation of motor neuron-specific miRNAs, such as Amyotrophic Lateral Sclerosis (ALS).